Is Fast-Growing Small-Cap Tasty Plc A Better Investment Than Stalwart GlaxoSmithKline plc?

Escalating profits from small-caps such as Tasty Plc (LON: TAST) can neutralise extra risk, so need we buy stalwarts such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s tempting to view firms with small market capitalisations as more risky investments than large FTSE 100 constituent companies.

However, big-cap firms can have their operational ups and downs, too. We only need to remember the recent big-cap share-price plunges of Royal Bank of Scotland, BP, Man Group and others to see how operational risks can affect our holdings in even the biggest of London-listed companies.

Risk and potential reward

Risk comes with all stock market investment, but companies with smaller market capitalisations often offer potentially greater rewards than many of the big-cap stalwarts. When a small-cap investment goes well, big capital returns can reduce the risk of holding shares in smaller firms by providing a cushion of investor profits to absorb ongoing share price and operational fluctuations.

Let’s compare the recent investor returns from defensive pharmaceutical Goliath GlaxoSmithKline (LSE: GSK) and fast-growing restaurant rollout and upstart company Tasty (TAST):

 

Market capitalisation

Index/market

Share price 3/1/13

Share price  30/3/15

Dividends

Total return

GlaxoSmithKline

£76,354 m

FTSE 100

1363p

1584p

175p

29%

Tasty

£73 m

AIM

51p

139p

0

173%

Tasty delivered investors nearly six times the return of GlaxoSmithKline over the last two years or so, and there’s every reason to expect the restaurant chain to go on beating the pharmaceutical giant in the years to come.

On a roll

Tasty’s restaurant rollout programme is going well. Monday’s full-year results revealed the firm added seven new outlets during 2014 and a further three since the end of the year, bringing the total number of outlets to 39.

The firm is operating at an opportune point in the general macro-economic cycle, with the nation’s finances in recovery mode, and the discretionary pound finding its way back into consumers’ pockets. Tasty builds its business by attracting discretionary (non-essential) spending with its mostly Wildwood-branded pizza, pasta and good-times restaurants.

The firm’s success shows in the numbers; revenue is up 28%, gross profit up 26% and pre-tax profit up 46% on the year-ago figures.

Plodding on

GlaxoSmithKline’s financial outcome for 2014 couldn’t be more different from Tasty’s. The firm posted turnover down 7% at constant exchange rates, and operating profit and earnings per share both down 40% compared to a year ago.

It’s no secret that the big London-listed pharmaceutical leviathans are rebuilding their product lines after patents expired on many bestsellers, allowing generic competition to swamp the market and wash away profits. However, even with the firm’s promising pipeline, it’s hard to imagine GlaxoSmithKline’s lumbering, slow-growing business model, and the company’s sheer size, ever producing investor returns to rival Tasty’s.

Stalwarts such as GlaxoSmithKline attract for their defensive, consistent cash-producing qualities, but we individual investors can build up sizeable cash-cushions of our own with shares of small-cap firms such as Tasty when they deliver on their strategic objectives.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold owns shares in Tasty plc. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

In a cyclical downturn, is there a buying opportunity in Croda shares?

With a positive sales outlook for 2024, is there a buying opportunity in Croda shares ahead of a potential recovery…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

£20,000 in savings? Here’s how I’d aim for £14,710 a year in passive income

With spare savings, this Fool would start generating passive income for a more comfortable retirement. Here he details how he'd…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,000 in savings? Here’s how I’d try to turn that into £581 a month of passive income

Relatively small investments in high-yielding stocks can grow through the power of dividend compounding into significant passive income.

Read more »

Photo of a man going through financial problems
Investing Articles

These are the FTSE’s biggest dogs over the last year!

The FTSE 100 has fallen far behind other major market indices over the past 12 months. However, these three sliding…

Read more »

Investing Articles

My top 3 stock market lessons from the Nvidia volcano eruption

Can we learn anything from the explosive rise in Nvidia's share price? Here are three Foolish reflections from this stock…

Read more »

Abstract 3d arrows with rocket
Investing Articles

Is boohoo the best near-penny stock to buy today?

This Fool asks why the boohoo share price has collapsed and whether now might be a good time to invest…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »